Efficacy and safety of neoadjuvant nab‐paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single‐arm phase II study (NAC‐GA trial)

BACKGROUND: Nab‐paclitaxel plus gemcitabine is a standard treatment for metastatic/locally advanced pancreatic cancer. The effectiveness of neoadjuvant therapy with nab‐paclitaxel plus gemcitabine (GnP‐NAT) in patients with borderline resectable pancreatic cancer (BRPC) remains unclear. PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Ken‐ichi, Kimura, Kenjiro, Yamashita, Yo‐Ichi, Shibuya, Kazuto, Matsumoto, Ippei, Satoi, Sohei, Yoshida, Kazuhiro, Kodera, Yasuhiro, Akahori, Takahiro, Hirono, Seiko, Eguchi, Hidetoshi, Asakuma, Mitsuhiro, Tani, Masaji, Hatano, Etsuro, Ikoma, Hisashi, Ohira, Go, Hayashi, Hiromitsu, Wan, Ke, Shimokawa, Toshio, Kawai, Manabu, Yamaue, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623952/
https://www.ncbi.nlm.nih.gov/pubmed/37927936
http://dx.doi.org/10.1002/ags3.12712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623952/
https://www.ncbi.nlm.nih.gov/pubmed/37927936
http://dx.doi.org/10.1002/ags3.12712

Ejemplares similares